Skip to Content

Duvelisib use while Breastfeeding

Drugs containing Duvelisib: Copiktra

Medically reviewed by Drugs.com. Last updated on April 7, 2021.

Duvelisib Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of duvelisib during breastfeeding. Because duvelisib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during duvelisib therapy and for at least 1 month after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Duvelisib

CAS Registry Number

1201438-56-3

Drug Class

Lactation

Breast Feeding

Antineoplastic Agents

Enzyme Inhibitors

Kinase Inhibitors

Phosphatidylinositol 3-kinases

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.